Gut microbiome interactions with drug metabolism, efficacy, and toxicity

Host-gut microbiota metabolic interactions

Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760 · see citing works

Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation

Dethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421 · see citing works

Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine

Hooper, L. V., Wong, M. H., Thelin, A., Hansson, L., Falk, P. G., & Gordon, J. I. (2001) · Science · doi:10.1126/science.291.5505.881 · Cited by 2,202 · see citing works

Proton pump inhibitors affect the gut microbiome

Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · see citing works

Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism

Nicholson, J. K., & Wilson, I. D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1157 · Cited by 1,121 · see citing works

Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080 · see citing works

Long-term impacts of antibiotic exposure on the human intestinal microbiota

Jernberg, C., Löfmark, S., Edlund, C., & Jansson, J. K. (2010) · Microbiology · doi:10.1099/mic.0.040618-0 · Cited by 1,067 · see citing works

Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4

Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., Qiu, Z., Maher, L., Redinbo, M. R., Phillips, R. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.014 · Cited by 1,066 · see citing works

Gut microorganisms, mammalian metabolism and personalized health care

Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1152 · Cited by 945 · see citing works

Proton pump inhibitors alter the composition of the gut microbiota

Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895 · see citing works

Xenobiotics shape the physiology and gene expression of the active human gut microbiome

Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811 · see citing works

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., & Nicholson, J. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904489106 · Cited by 765 · see citing works

Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium <i>Eggerthella lenta</i>

Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704 · see citing works

Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation

Hubbard, T. D., Murray, I. A., & Perdew, G. H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064246 · Cited by 646 · see citing works

THE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE

PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450 · see citing works

Colonization-induced host-gut microbial metabolic interaction

Claus, S. P., Ellero, S. L., Berger, B., Krause, L., Bruttin, A., Molina, J., Paris, A., Want, E. J., de Waziers, I., Cloarec, O., et al. (2011) · mBio · doi:10.1128/mbio.00271-10 · Cited by 414 · see citing works

Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats

Bowey, E. A., Adlercreutz, H., & Rowland, I. (2003) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00324-1 · Cited by 381 · see citing works

Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles

Hubbard, T. D., Murray, I. A., Bisson, W. H., Lahoti, T. S., Gowda, K., Amin, S. G., Patterson, A. D., & Perdew, G. H. (2015) · Scientific Reports · doi:10.1038/srep12689 · Cited by 377 · see citing works

Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases

Hein, D. W., Doll, M. A., Rustan, T. D., Gray, K. A., Feng, Y., Ferguson, R. J., & Grant, D. M. (1993) · Carcinogenesis · doi:10.1093/carcin/14.8.1633 · Cited by 359 · see citing works

The challenges of modeling mammalian biocomplexity

Nicholson, J. K., Holmes, E. C., Lindon, J. C., & Wilson, I. D. (2004) · Nature Biotechnology · doi:10.1038/nbt1015 · Cited by 357 · see citing works

The influence of non-steroidal anti-inflammatory drugs on the gut microbiome

Rogers, M. A. M., & Aronoff, D. M. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.003 · Cited by 346 · see citing works

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1996) · PubMed · Cited by 336 · see citing works

Quercetin Derivatives Are Deconjugated and Converted to Hydroxyphenylacetic Acids but Not Methylated by Human Fecal Flora in Vitro

Aura, A., O’Leary, K. A., Williamson, G., Ojala, M., Bailey, M., Puupponen‐Pimiä, R., Nuutila, A. M., Oksman‐Caldentey, K., & Poutanen, K. S. (2002) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0108056 · Cited by 306 · see citing works

Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity

Wallace, B. D., Roberts, A. B., Pollet, R. M., Ingle, J. D., Biernat, K. A., Pellock, S. J., Venkatesh, M. K., Guthrie, L., O’Neal, S. K., Robinson, S. J., et al. (2015) · Chemistry &amp; Biology · doi:10.1016/j.chembiol.2015.08.005 · Cited by 285 · see citing works

Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics

Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268 · see citing works

Digoxin-Inactivating Bacteria: Identification in Human Gut Flora

Dobkin, J. F., Saha, J. R., Butler, V. P., Neu, H. C., & Lindenbaum, J. (1983) · Science · doi:10.1126/science.6836275 · Cited by 259 · see citing works

Balicalin, the Predominant Flavone Glucuronide of Scutellariae Radix, is Absorbed from the Rat Gastrointestinal Tract as the Aglycone and Restored to its Original Form

Akao, T., Kawabata, K., Yanagisawa, E., Ishihara, K., Mizuhara, Y., Wakui, Y., Sakashita, Y., & Kobashi, K. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001777621 · Cited by 252 · see citing works

Intestinal Microbiota Regulate Xenobiotic Metabolism in the Liver

Björkholm, B., Bok, C. M., Lundin, A., Rafter, J., Hibberd, M. L., & Pettersson, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006958 · Cited by 249 · see citing works

The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition

Mäkivuokko, H., Tiihonen, K., Tynkkynen, S., Paulin, L. G., & Rautonen, N. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509991553 · Cited by 243 · see citing works

Therapeutic Modulation of Microbiota-Host Metabolic Interactions

Holmes, E. C., Kinross, J. K., Gibson, G. R., Burcelin, R., Jia, W. P., Pettersson, S., & Nicholson, J. K. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004244 · Cited by 235 · see citing works

Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids

Klaassen, C. D., & Cui, J. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065698 · Cited by 208 · see citing works

<i>Helicobacter pylori</i> eradication and l-dopa absorption in patients with PD and motor fluctuations

Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199 · see citing works

Mechanistic insight into digoxin inactivation by <i>Eggerthella lenta</i> augments our understanding of its pharmacokinetics

Haiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197 · see citing works

Pharmacologic Targeting of Bacterial β-Glucuronidase Alleviates Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice

LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R., & Boelsterli, U. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191122 · Cited by 197 · see citing works

Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?

Swanson, H. I. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065714 · Cited by 179 · see citing works

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

Chan, R. P., POPE, D. J., Gilbert, A. P., Sacra, P. J., Baron, J. H., & Lennard-Jones, J. E. (1983) · Digestive Diseases and Sciences · doi:10.1007/bf01299921 · Cited by 167 · see citing works

A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors

Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna‐Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.13568 · Cited by 166 · see citing works

Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes

Saad, R., Rizkallah, M. R., & Aziz, R. K. (2012) · Gut Pathogens · doi:10.1186/1757-4749-4-16 · Cited by 165 · see citing works

Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics

Saitta, K. S., Zhang, C., Lee, K. K., Fujimoto, K., Redinbo, M. R., & Boelsterli, U. A. (2014) · Xenobiotica · doi:10.3109/00498254.2013.811314 · Cited by 165 · see citing works

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility

Seto, C. T., Jeraldo, P., Orenstein, R., Chia, N., & DiBaise, J. K. (2014) · Microbiome · doi:10.1186/2049-2618-2-42 · Cited by 163 · see citing works

Gut microbiota-mediated drug interactions between lovastatin and antibiotics

Yoo, D.-H., Kim, I. S., Van Le, T. K., Jung, I.-H., Yoo, H. H., & Kim, D.-H. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058354 · Cited by 158 · see citing works

A Possible Mechanism of Eighteen Patient Deaths Caused by Interactions of Sorivudine, a New Antiviral Drug, with Oral 5-Fluorouracil Prodrugs

Okuda, H., Ogura, K., Kato, A., Takubo, H., & Watabe, T. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37858-9 · Cited by 155 · see citing works

The Effect of Proton Pump Inhibitors on the Human Microbiota

Vesper, B. J., Jawdi, A., Altman, K. W., Haines, G. K., Tao, L., & Radosevich, J. A. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048392 · Cited by 145 · see citing works

Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics

Selwyn, F. P., Cheng, S. L., Klaassen, C. D., & Cui, J. Y. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067504 · Cited by 138 · see citing works

Eradication of Helicobacter pylori Infection Improves Levodopa Action, Clinical Symptoms and Quality of Life in Patients with Parkinson's Disease

Hashim, H., Azmin, S., Razlan, H., Yahya, N. W., Tan, H. J., Manaf, M. R. A., & Ibrahim, N. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112330 · Cited by 136 · see citing works

The metabolism of orally administered l ‐DOPA in Parkinsonism

Calne, D. B., Karoum, F., Ruthven, C. R. J., & SANDLER, M. (1969) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1969.tb09522.x · Cited by 135 · see citing works

Is It Time for a Metagenomic Basis of Therapeutics?

Haiser, H. J., & Turnbaugh, P. J. (2012) · Science · doi:10.1126/science.1224396 · Cited by 133 · see citing works

Untitled work

(2000) · PubMed · Cited by 131 · see citing works

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora

Harris, B., Manning, B. W., Federle, T. W., & Diasio, R. B. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.1.44 · Cited by 128 · see citing works

Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study

Endo, H., Higurashi, T., Hosono, K., Sakai, E., Sekino, Y., Iida, H., Sakamoto, Y., Koide, T., Takahashi, H., Yoneda, M., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0410-1 · Cited by 123 · see citing works

Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil

Nakayama, H., Kinouchi, T., Kataoka, K., Akimoto, S., Matsuda, Y., & Ohnishi, Y. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00005 · Cited by 120 · see citing works

The effect of gut microbiota on drug metabolism

Kang, M. J., Kim, H. G., Kim, J. S., Oh, D. G., Um, Y. J., Seo, C. S., Han, J. W., Cho, H. J., Kim, G. H., Jeong, T. C., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.807798 · Cited by 120 · see citing works

Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050818 · Cited by 120 · see citing works

Identification and Functional Characterization of Arylamine <i>N</i> -Acetyltransferases in Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid

Deloménie, C., Fouix, S., Longuemaux, S., Brahimi, N., Bizet, C., Picard, B., Denamur, E., & Dupret, J.-M. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.11.3417-3427.2001 · Cited by 117 · see citing works

The Role of the Gut Flora in the Metabolism of Prontosil and Neoprontosil in the Rat

Gingell, R., Bridges, J. W., & Williams, R. T. (1971) · Xenobiotica · doi:10.3109/00498257109044386 · Cited by 117 · see citing works

Studies of the metabolism of methotrexate by intestinal flora—I

Valerino, D. M., Johns, D. G., Zaharko, D. S., & Oliverio, V. T. (1972) · Biochemical Pharmacology · doi:10.1016/0006-2952(72)90125-6 · Cited by 115 · see citing works

Acetamide—a metabolite of metronidazole formed by the intestinal flora

Koch, R. L., Chrystal, E. J. T., Beaulieu, B. B., & Goldman, P. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90407-6 · Cited by 111 · see citing works

The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains

Dawson, L. F., Donahue, E. H., Cartman, S. T., Barton, R. H., Bundy, J. G., McNerney, R., Minton, N. P., & Wren, B. W. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-86 · Cited by 110 · see citing works

Chloramphenicol toxicity: 25 years of research.

Yunis, A. A. (1989) · PubMed · Cited by 106 · see citing works

Colonic metabolism of ranitidine: implications for its delivery and absorption

Basit, A. W., & Lacey, L. F. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00794-3 · Cited by 105 · see citing works

Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract.

Rafii, F., & Cerniglia, C. E. (1995) · Environmental Health Perspectives · doi:10.1289/ehp.95103s417 · Cited by 104 · see citing works

Bioactive Isoflavones in Functional Foods: The Importance of Gut Microflora on Bioavailability

Turner, N. J., Thomson, B., & Shaw, I. C. (2003) · Nutrition Reviews · doi:10.1301/nr.2003.jun.204-213 · Cited by 103 · see citing works

Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines.

Grant, D., Josephy, P. D., Lord, H. L., & Morrison, L. D. (1992) · PubMed · Cited by 101 · see citing works

Bidirectional interactions between indomethacin and the murine intestinal microbiota

Liang, X., Bittinger, K. L., Li, X., Abernethy, D. R., Bushman, F. D., & FitzGerald, G. A. (2015) · eLife · doi:10.7554/elife.08973 · Cited by 101 · see citing works

Intestinal flora induces the expression of Cyp3a in the mouse liver

Toda, T., Saito, N., Ikarashi, N., Ito, K., Yamamoto, M., ISHIGE, A., Watanabe, K., & Sugiyama, K. (2009) · Xenobiotica · doi:10.1080/00498250802651984 · Cited by 99 · see citing works

The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid.

Koch, R. L., & Goldman, P. (1979) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31588-0 · Cited by 98 · see citing works

Impact of Gut Microbiota on Intestinal and Hepatic Levels of Phase 2 Xenobiotic-Metabolizing Enzymes in the Rat

Meinl, W., Sczesny, S., Brigelius‐Flohé, R., Blaut, M., & Glatt, H. R. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025916 · Cited by 96 · see citing works

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

Sweeny, D. J., Li, W., Clough, J., Bhamidipati, S., Singh, R., Park, G., Baluom, M., Grossbard, E. B., & Lau, D. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032151 · Cited by 93 · see citing works

Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity

Li, H., & Jia, W. P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.157 · Cited by 93 · see citing works

Nonsteroidal Anti-inflammatory Drugs, Proton Pump Inhibitors, and Gastrointestinal Injury: Contrasting Interactions in the Stomach and Small Intestine

Marlicz, W., Łoniewski, I., Grimes, D. S., & Quigley, E. M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.015 · Cited by 91 · see citing works

CONTRIBUTIONS OF HOST AND INTESTINAL MICROFLORA IN THE METABOLISM OF l-DOPA BY THE RAT

Goldin, B. R., Peppercorn, M. A., & Goldman, P. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29577-5 · Cited by 91 · see citing works

Old drug new use - Amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity

Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90 · see citing works

The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds

Cole, C. B., Fuller, R., Mallet, A., & Rowland, I. R. (1985) · Journal of Applied Bacteriology · doi:10.1111/j.1365-2672.1985.tb03359.x · Cited by 88 · see citing works

Antibiotics Alter Methotrexate Metabolism and Excretion

Zaharko, D. S., Bruckner, H. W., & Oliverio, V. T. (1969) · Science · doi:10.1126/science.166.3907.887 · Cited by 87 · see citing works

The Role of Mammalian Intestinal Bacteria in the Reductive Metabolism of Zonisamide

Kitamura, S., Sugihara, K., Kuwasako, M., & Tatsumi, K. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06790.x · Cited by 86 · see citing works

Degradation of Insulin and Calcitonin and Their Protection by Various Protease Inhibitors in Rat Caecal Contents: Implications in Peptide Delivery to the Colon

Tozaki, H., Emi, Y., Horisaka, E., Fujita, T., Yamamoto, A., & Muranishi, S. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06773.x · Cited by 84 · see citing works

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea

Takasuna, K., Hagiwara, T., Watanabe, K., Onose, S., Yoshida, S., Kumazawa, E., Nagai, E., & Kamataki, T. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0187-8 · Cited by 83 · see citing works

THE BACTERIAL DEGRADATION OF CHLORAMPHENICOL

HOLT, R. (1967) · The Lancet · doi:10.1016/s0140-6736(67)92720-1 · Cited by 81 · see citing works

Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora

Basit, A. W., NEWTON, J. M., & Lacey, L. F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00018-2 · Cited by 81 · see citing works

In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?

Niehues, M., & Hensel, A. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.10.0005 · Cited by 77 · see citing works

Urinary excretion of reduced metabolites of digoxin

Lindenbaum, J., Tse-Eng, D., Butler, V. P., & Rund, D. G. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90260-6 · Cited by 75 · see citing works

The metabolism and excretion of risperidone after oral administration in rats and dogs.

Meuldermans, W., Hendrickx, J., Mannens, G., Lavrijsen, K., Janssen, C., Bracke, J., Jeune, L. L., Lauwers, W., & Heykants, J. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08286-8 · Cited by 73 · see citing works

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators

Antila, S., Pesonen, U., Lehtonen, L., Tapanainen, P., Nikkanen, H., Vaahtera, K., & Scheinin, H. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.07.005 · Cited by 70 · see citing works

The reduction of sulphinpyrazone and sulindac by intestinal bacteria

Strong, H. A., RENWICK, A. G., George, C. F., Liu, Y. F., & Hill, M. J. (1987) · Xenobiotica · doi:10.3109/00498258709043976 · Cited by 70 · see citing works

Involvement of the intestinal microflora in nitrazepam‐induced teratogenicity in rats and its relationship to nitroreduction

Takeno, S., & Sakai, T. (1991) · Teratology · doi:10.1002/tera.1420440209 · Cited by 69 · see citing works

Therapeutic Implications in Parkinsonism of m-Tyramine Formation from L-Dopa in Man

SANDLER, M., Goodwin, B. L., Ruthven, C. R. J., & Calne, D. B. (1971) · Nature · doi:10.1038/229414a0 · Cited by 67 · see citing works

Role of the intestinal microflora in clonazepam metabolism in the rat

Elmer, G. W., & Remmel, R. P. (1984) · Xenobiotica · doi:10.3109/00498258409151481 · Cited by 63 · see citing works

Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora.

Mathan, V. I., Wiederman, J., Dobkin, J. F., & Lindenbaum, J. (1989) · Gut · doi:10.1136/gut.30.7.971 · Cited by 62 · see citing works

Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.

Lavrijsen, K., Dyck, D. V., Houdt, J. V., Hendrickx, J., Monbaliu, J. G., Woestenborghs, R. J. H., Meuldermans, W., & Heykants, J. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06545-6 · Cited by 59 · see citing works

In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?

Niehues, M., & Hensel, A. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp/61.10.0005 · Cited by 59 · see citing works

Ciprofloxacin Suppresses Cyp3a in Mouse Liver by Reducing Lithocholic Acid-producing Intestinal Flora

Toda, T., Ohi, K., Kudo, T., Yoshida, T., Ikarashi, N., Ito, K., & Sugiyama, K. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.201 · Cited by 58 · see citing works

Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria

Shu, Y. ‐., Kingston, D. G. I., Tassell, R. L. V., & Wilkins, T. D. (1991) · Xenobiotica · doi:10.3109/00498259109039513 · Cited by 56 · see citing works

The demethylation of methamphetamine by intestinal microflora

Caldwell, J., & HAWKSWORTH, G. M. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10043.x · Cited by 54 · see citing works

Site dependent bioavailability and metabolism of levosimendan in dogs

Antila, S., Huuskonen, H., Nevalainen, T. O., Kanerva, H., Vanninen, P. S., & Lehtonen, L. (1999) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(99)00048-2 · Cited by 53 · see citing works

Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol

Jimenez, J., Arimura, G. K., Abou-Khalil, W. H., Isildar, M., & Yunis, A. A. (1987) · Blood · doi:10.1182/blood.v70.4.1180.bloodjournal7041180 · Cited by 52 · see citing works

An in vitro Study on the Active Conversion of Flucytosine to Fluorouracil by Microorganisms in the Human Intestinal Microflora

Vermes, A., Kuijper, E. J., Guchelaar, H., & Dankert, J. (2003) · Chemotherapy · doi:10.1159/000069784 · Cited by 49 · see citing works

Anaerobic metabolism of 2-amino-3-methyl-3H-imidazo[4,5-f]quinoline (IQ) by human fecal flora

Bashir, M., Kingston, D. G. I., Carman, R. J., Tassell, R. L. V., & Wilkins, T. D. (1987) · Mutation Research Letters · doi:10.1016/0165-7992(87)90027-3 · Cited by 49 · see citing works

BIOACTIVATION OF 4-METHYLPHENOL (p-CRESOL) VIA CYTOCHROME P450-MEDIATED AROMATIC OXIDATION IN HUMAN LIVER MICROSOMES

Yan, Z., Zhong, H. M., Maher, N., Torres, R., Leo, G. C., Caldwell, G. W., & Huebert, N. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006387 · Cited by 49 · see citing works

Digoxin Inactivation by the Gut Flora in Infancy and Childhood

Linday, L. A., Dobkin, J. F., Wang, T. C., Butler, V. P., Saha, J. R., & Lindenbaum, J. (1987) · PEDIATRICS · doi:10.1542/peds.79.4.544 · Cited by 48 · see citing works

Role of the intestinal flora in the metabolism of misonidazole

Koch, R. L., Beaulieu, B. B., & Goldman, P. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90304-4 · Cited by 48 · see citing works

Azo Reduction of Salicyl-Azo-Sulphapyridine in Germ-free and Conventional Rats

Schröder, H., & Gustafsson, B. E. (1973) · Xenobiotica · doi:10.3109/00498257309151518 · Cited by 48 · see citing works

Influence of Gut Microflora on Bioavailability

Boxenbaum, H. G., Bekersky, I., Jack, M. L., & Kaplant, S. A. (1979) · Drug Metabolism Reviews · doi:10.3109/03602537908993894 · Cited by 48 · see citing works

The human colonic microflora influences the alterations of xenobiotic-metabolizing enzymes by catechins in male F344 rats

Lhoste, E. F., Ouriet, V., Bruel, S., Flinois, J.-P., Brézillon, C., Magdalou, J., Chèze, C., & Nugon-Baudon, L. (2003) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(03)00010-3 · Cited by 45 · see citing works

Metabolism of Omeprazole by Gut Flora in Rats

Watanabe, K., Yamashita, S., Furuno, K., Kawasaki, H., & Gomita, Y. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840425 · Cited by 44 · see citing works

Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative

Stiff, D. D., Robicheau, J. T., & Zemaitis, M. A. (1992) · Xenobiotica · doi:10.3109/00498259209053097 · Cited by 44 · see citing works

Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors

Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E. (2012) · SLAS Discovery · doi:10.1177/1087057112444927 · Cited by 44 · see citing works

Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora.

Dobkin, J. F., Saha, J. R., BUTLER, V. P. J., Neu, H. C., & Lindenbaum, J. (1982) · PubMed · Cited by 42 · see citing works

Role of the intestinal flora in the acetylation of sulfasalazine metabolites

Dull, B. J., Salata, K., & Goldman, P. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90034-7 · Cited by 42 · see citing works

Role of intestinal microflora in xenobiotic‐induced toxicity

Jeong, H. G., Kang, M. J., Kim, H. G., Oh, D. G., Kim, J. S., Lee, S., & Jeong, T. C. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200461 · Cited by 42 · see citing works

The Role of Intestinal Bacteria in the Transformation of Sodium Picosulfate

Kim, D., Hyun, S.-H., Shim, S.-B., & Kobashi, K. (1992) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.59.1 · Cited by 41 · see citing works

Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions

van Hogezand, R. A., Kennis, H. M., van Schaik, A., Koopman, J. P., van Hees, P. A. M., & van Tongeren, J. H. M. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf01740669 · Cited by 40 · see citing works

Metabolism ofN-Acylated andO-Alkylated Drugs by the Intestinal Microflora During Anaerobic Incubationin vitro

Smith, G., & Griffiths, L. A. (1974) · Xenobiotica · doi:10.3109/00498257409052100 · Cited by 40 · see citing works

The Inhibitory Effect of Ciprofloxacin on the β‐Glucuronidase‐mediated Deconjugation of the Irinotecan Metabolite SN‐38‐G

Kodawara, T., Higashi, T., Negoro, Y., Kamitani, Y., Igarashi, T., Watanabe, K., Tsukamoto, H., Yano, R., Masada, M., Iwasaki, H., et al. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12511 · Cited by 39 · see citing works

Differences between Germ-free and Conventional Rats in Liver Microsomal Metabolism of Steroids

Einarsson, K., Gustafsson, J.-Α., & Gustafsson, B. E. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43974-4 · Cited by 38 · see citing works

Xenobiotics and the Human Gut Microbiome: Metatranscriptomics Reveal the Active Players

Ursell, L. K., & Knight, R. D. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.013 · Cited by 37 · see citing works

3,4-Dihydroxyphenylacetic acid, a microbiota-derived metabolite of quercetin, attenuates acetaminophen (APAP)-induced liver injury through activation of Nrf-2

Xue, H., Xie, W., Jiang, Z., Wang, M., Wang, J., Zhao, H., & Zhang, X. (2016) · Xenobiotica · doi:10.3109/00498254.2016.1140847 · Cited by 36 · see citing works

Pancreatitis Associated with Olsalazine and Sulfasalazine in Children with Ulcerative Colitis

Garau, P., Orenstein, S. R., Neigut, D. A., & Kocoshis, S. A. (1994) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199405000-00015 · Cited by 36 · see citing works

Medicine and the Law

Hill, M. M. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91886-5 · Cited by 36 · see citing works

Tissue Distribution and Biotransformation of Potassium Oxonate after Oral Administration of a Novel Antitumor Agent (Drug Combination of Tegafur, 5-Chloro-2,4-dihydroxypyridine, and Potassium Oxonate) to Rats

Yoshisue, K., MASUDA, H., Matsushima, E., Ikeda, K., Nagayama, S., & KAWAGUCHI, Y. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12044-5 · Cited by 35 · see citing works

Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ‐free rats

Lee, S. H., An, J. H., Lee, H. J., & Jung, B. H. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1799 · Cited by 32 · see citing works

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs

Sasahara, K., Nitanai, T., Habara, T., Kojima, T., Kawahara, Y., Morioka, T., & Nakajima, E. (1981) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600700705 · Cited by 32 · see citing works

Techniques for microfloral and associated metabolic studies in relation to the absorption and enterohepatic circulation of drugs

Illing, H. P. A. (1981) · Xenobiotica · doi:10.3109/00498258109045319 · Cited by 31 · see citing works

The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol

Mikov, M., Caldwell, J., Dolphin, C. T., & Smith, R. L. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90005-6 · Cited by 27 · see citing works

Intestinal Azo-reduction and Glucuronide Conjugation of Prontosil

Gingell, R., & Bridges, J. W. (1973) · Xenobiotica · doi:10.3109/00498257309151548 · Cited by 24 · see citing works

Metabolism of peptide drugs by the microorganisms in rat cecal contents.

Tozaki, H., Yasuharu, E. M. I., Horisaka, E., FUJITA, T., Yamamoto, A., & Muranishi, S. (1995) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.18.929 · Cited by 24 · see citing works

Role of intestinal flora in metabolism of agrochemicals conjugated with glutathione

Bakke, J. E., & Gustafsson, J.-Α. (1986) · Xenobiotica · doi:10.3109/00498258609038982 · Cited by 23 · see citing works

Degradation of DOPA by Intestinal Microorganisms in Vitro

Bakke, O. M. (1971) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1971.tb00640.x · Cited by 22 · see citing works

Metabolism of Azetirelin, a New Thyrotropin-releasing Hormone (TRH) Analogue, by Intestinal Microorganisms

Sasaki, I., Tamura, T., Shibakawa, T., Fujita, T., Murakami, M., Yamamoto, A., & Muranishi, S. (1997) · Pharmaceutical Research · doi:10.1023/a:1012141025938 · Cited by 19 · see citing works

Discovery of Specific Inhibitors for Intestinal E. coli β‐Glucuronidase through In Silico Virtual Screening

Cheng, T.-C., Chuang, K.-H., Roffler, S. R., Cheng, K.-W., Leu, Y.-L., Chuang, C., Huang, C.-C., Kao, C.-H., Hsieh, Y.-C., Chang, L., et al. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/740815 · Cited by 17 · see citing works

Selective expression of detoxifying glutathione transferases in mouse colon: effect of experimental colitis and the presence of bacteria

Edalat, M., Mannervik, B., & Axelsson, L. ‐. (2004) · Histochemistry and Cell Biology · doi:10.1007/s00418-004-0688-7 · Cited by 17 · see citing works

Dietary influence on caecal microbial nitroreduction of a drug: metronidazole.

Wise, A., & Gilburt, D. J. (1982) · PubMed · Cited by 15 · see citing works

Evolution of Olsalazine

Truelove, S. C. (1988) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528809101538 · Cited by 14 · see citing works

Investigations of Hydrazine Cleavage of Eltrombopag in Humans

Deng, Y., Rogers, M., Sychterz, C. J., Talley, K., Qian, Y., Bershas, D. A., Ho, M. Y. K., Shi, W., Chen, E. P., Serabjit‐Singh, C. J., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040188 · Cited by 14 · see citing works

Development of an Oral Formulation of Azetirelin, a New Thyrotropin-Releasing Hormone (TRH) Analogue, Using n-Lauryl-.BETA.-D-maltopyranoside as an Absorption Enhacer.

SAKAI, I., Tozaki, H., MATASUMOTO, K., Ito, Y., Fujita, T., Murakami, M., Muranishi, S., & Yamamoto, A. (1999) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.22.611 · Cited by 13 · see citing works

Degradation of bromazepam by the intestinal microflora.

Fujii, J., Inotsume, N., & Nakano, M. (1987) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.35.4338 · Cited by 13 · see citing works

Mutagen Activation by Hepatic Fractions from Conventional, Germfree and Monoassociated Rats

Rowland, I. R., Mallett, A. K., Cole, C. B., & Fuller, R. (1987) · Springer eBooks · doi:10.1007/978-3-642-72558-6_47 · Cited by 8 · see citing works

Colonisation with digoxin-reducing strains of Eubacterium lentum and Clostridium difficile infection in nursing home patients.

Bennett, R. G., Beamer, B. A., Greenough, W. B., Lindenbaum, J., & Bartlett, J. G. (1992) · PubMed · Cited by 7 · see citing works

Intestinal microflora as potential modifiers of sensitizer activity in vivo

SHELDON, P. W., Clarke, C., Dawson, K. B., Simpson, W., & Simmons, D. J. C. (1984) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(84)90351-1 · Cited by 7 · see citing works

Gut microbiota-derived metabolites as key actors in inflammatory bowel disease

Lavelle, A., & Sokol, H. (2020) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0258-z · Cited by 2,015 · see citing works

An insight into gut microbiota and its functionalities

Adak, A., & Khan, M. R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2943-4 · Cited by 1,485 · see citing works

Mapping human microbiome drug metabolism by gut bacteria and their genes

Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160 · see citing works

Microbiota: a key orchestrator of cancer therapy

Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883 · see citing works

Non-invasive delivery strategies for biologics

Anselmo, A. C., Gokarn, Y. R., & Mitragotri, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 671 · see citing works

The Gut Microbiota in Inflammatory Bowel Disease

Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.733992 · Cited by 599 · see citing works

Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies

Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00431 · Cited by 543 · see citing works

Emerging issues in probiotic safety: 2023 perspectives

Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185034 · Cited by 481 · see citing works

How nutrition and the maternal microbiota shape the neonatal immune system

Macpherson, A. J., de Agüero, M. G., & Ganal-Vonarburg, S. C. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.58 · Cited by 378 · see citing works

The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group

Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M. F., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 414 · see citing works

Gut microbiota, a new frontier to understand traditional Chinese medicines

Feng, W., Ao, H., Peng, C. Y., & Yan, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.024 · Cited by 379 · see citing works

A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research

Poyet, M., Groussin, M., Gibbons, S. M., Ávila-Pacheco, J., Jiang, X., Kearney, S. M., Perrotta, A. R., Berdy, B. M., Zhao, S., Lieberman, T. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0559-3 · Cited by 365 · see citing works

Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review

Vinarov, Z., Abdallah, M., Agúndez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M. F., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 380 · see citing works

Advancing functional and translational microbiome research using meta-omics approaches

Zhang, X., Li, L., Butcher, J., Stintzi, A. P., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 342 · see citing works

Gut reactions: Breaking down xenobiotic–microbiome interactions

Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319 · see citing works

Drug induced liver injury: an update

García‐Cortés, M., Robles‐Díaz, M., Stephens, C. M., Ortega‐Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 302 · see citing works

Drug-microbiota interactions: an emerging priority for precision medicine

Zhao, Q. C., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 296 · see citing works

Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms

Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262 · see citing works

The influence of the gut microbiota on the bioavailability of oral drugs

Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 246 · see citing works

Microbiota and Thyroid Interaction in Health and Disease

Fröhlich, E., & Wahl, R. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.008 · Cited by 233 · see citing works

Human Gut Microbiota and Drug Metabolism

Pant, A., Maiti, T. K., Mahajan, D., & Das, B. (2022) · Microbial Ecology · doi:10.1007/s00248-022-02081-x · Cited by 228 · see citing works

The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer

Lü, Y., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., & Xu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.165 · Cited by 211 · see citing works

Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits - a comprehensive review

El‐Saadony, M. T., Saad, A. M., Mohammed, D. M., Korma, S. A., Alshahrani, M. Y., Ahmed, A. E., Ibrahim, E. H., Salem, H. M., Alkafaas, S. S., Saif, A. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1491777 · Cited by 269 · see citing works

<i>Lactobacillus</i> bile salt hydrolase substrate specificity governs bacterial fitness and host colonization

Foley, M. H., O’Flaherty, S., Allen, G., Rivera, A. J., Stewart, A. K., Barrangou, R., & Theriot, C. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017709118 · Cited by 205 · see citing works

Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives

Badgeley, A., Anwar, H., Modi, K., Murphy, P., & Lakshmikuttyamma, A. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188494 · Cited by 203 · see citing works

Environmental Influences on the Human Microbiome and Implications for Noncommunicable Disease

Ahn, J., & Hayes, R. B. (2021) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-012420-105020 · Cited by 194 · see citing works

Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics

Li, D. X., Li, Y., Yang, S., Lu, J., Jin, X., & Wu, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113290 · Cited by 186 · see citing works

Taxonomic signatures of cause-specific mortality risk in human gut microbiome

Salosensaari, A., Laitinen, V., Havulinna, A. S., Méric, G., Cheng, S. C., Perola, M., Valsta, L. M., Alfthan, G., Inouye, M., Watrous, J. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22962-y · Cited by 168 · see citing works

Rare ginsenosides: A unique perspective of ginseng research

Fan, W., Fan, L., Wang, Z., Mei, Y., Liu, L., Li, L., Yang, L., & Wang, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.003 · Cited by 169 · see citing works

NSAID–Gut Microbiota Interactions

Maseda, D., & Ricciotti, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01153 · Cited by 166 · see citing works

Caution, “normal” BMI: health risks associated with potentially masked individual underweight—EPMA Position Paper 2021

Golubnitschaja, O., Líšková, A., Koklesová, L., Samec, M., Biringer, K., Büsselberg, D., Podbielska, H., Kunin, A. A., Evsevyeva, M. E., Shapira, N., et al. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00251-4 · Cited by 151 · see citing works

Drug–gut microbiota interactions: implications for neuropharmacology

Walsh, J., Griffin, B. T., Clarke, G. A., & Hyland, N. P. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14366 · Cited by 150 · see citing works

Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network

Vinarov, Z., Abrahamsson, B., Artursson, P., Batchelor, H. K., Berben, P., Bernkop‐Schnürch, A., Butler, J., Ceulemans, J., Davies, N. M., Dupont, D., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.001 · Cited by 155 · see citing works

The role of microbiome in rheumatoid arthritis treatment

Bodkhe, R., Balakrishnan, B., & Taneja, V. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19844632 · Cited by 146 · see citing works

Biomarker Research in Parkinson’s Disease Using Metabolite Profiling

Havelund, J. F., Heegaard, N. H. H., Færgeman, N. J., & Gramsbergen, J. B. (2017) · Metabolites · doi:10.3390/metabo7030042 · Cited by 145 · see citing works

Safety of Probiotics: Functional Fruit Beverages and Nutraceuticals

Žuntar, I., Petrić, Z., Kovačević, D. B., & Putnik, P. (2020) · Foods · doi:10.3390/foods9070947 · Cited by 142 · see citing works

An in vitro model maintaining taxon-specific functional activities of the gut microbiome

Li, L., Abou-Samra, E., Ning, Z., Zhang, X., Mayne, J., Wang, J., Cheng, K., Walker, K., Stintzi, A. P., & Figeys, D. (2019) · Nature Communications · doi:10.1038/s41467-019-12087-8 · Cited by 131 · see citing works

Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats

Yu, Y., Liu, Q., Li, H., Wen, C., & He, Z. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02233 · Cited by 129 · see citing works

Age-related changes in intestinal immunity and the microbiome

Walrath, T., Dyamenahalli, K. U., Hulsebus, H. J., McCullough, R. L., Idrovo, J., Boe, D. M., McMahan, R. H., & Kovacs, E. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ri0620-405rr · Cited by 124 · see citing works

The gut microbiome and mental health: advances in research and emerging priorities

Shoubridge, A. P., Choo, J. M., Martin, A. M., Keating, D. J., Wong, M., Licinio, J., & Rogers, G. B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01479-w · Cited by 130 · see citing works

Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora

Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 125 · see citing works

Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics

Abdelsalam, N. A., Ramadan, A. T., ElRakaiby, M. T., & Aziz, R. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00390 · Cited by 123 · see citing works

Towards a mechanistic understanding of reciprocal drug–microbiome interactions

Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 122 · see citing works

Effects of Antibiotic Treatment on Gut Microbiota and How to Overcome Its Negative Impacts on Human Health

Ribeiro, C. F. A., Silveira, G. G. D. O. S., Cândido, E. D. S., Cardoso, M. H. E. S., Carvalho, C. M. E., & Franco, O. L. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00036 · Cited by 121 · see citing works

Biotransformation: Impact and Application of Metabolism in Drug Discovery

Shanu-Wilson, J., Evans, L., Wrigley, S. K., Steele, J. C. P., Atherton, J., & Boer, J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00202 · Cited by 118 · see citing works

Self-reinoculation with fecal flora changes microbiota density and composition leading to an altered bile-acid profile in the mouse small intestine

Bogatyrev, S. R., Rolando, J. C., & Ismagilov, R. F. (2020) · Microbiome · doi:10.1186/s40168-020-0785-4 · Cited by 109 · see citing works

The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases

Yang, X., Lu, D., Zhuo, J., Lin, Z., Yang, M., & Xu, X. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.46405 · Cited by 109 · see citing works

Metabolic control by the microbiome

Cox, T. O., Lundgren, P., Nath, K., & Thaiss, C. A. (2022) · Genome Medicine · doi:10.1186/s13073-022-01092-0 · Cited by 113 · see citing works

No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases

Kell, D. B., & Pretorius, E. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12407 · Cited by 113 · see citing works

Microbiota–Host Transgenomic Metabolism, Bioactive Molecules from the Inside

Turroni, S., Brigidi, P., Cavalli, A., & Candela, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00244 · Cited by 107 · see citing works

Disease-modifying therapies alter gut microbial composition in MS

Sand, I. K., Zhu, Y., Ntranos, A., Clemente, J. C., Cekanaviciute, E., Brandstadter, R., Crabtree‐Hartman, E., Singh, S., Bencosme, Y., Debelius, J. W., et al. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000517 · Cited by 106 · see citing works

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Chiang, H., & Lin, C. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18067 · Cited by 104 · see citing works

Gut microbiota as an “invisible organ” that modulates the function of drugs

Li, X., Liu, L., Cao, Z., Li, W., Li, H., Lu, C. C., Yang, X., & Liu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109653 · Cited by 107 · see citing works

Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine

Beger, R. D., Schmidt, M. A., & Kaddurah-Daouk, R. F. (2020) · Metabolites · doi:10.3390/metabo10040129 · Cited by 103 · see citing works

Microalgae—Sustainable Source for Alternative Proteins and Functional Ingredients Promoting Gut and Liver Health

Eilam, Y., Khattib, H., Pintel, N., & Avni, D. (2023) · Global Challenges · doi:10.1002/gch2.202200177 · Cited by 101 · see citing works

Gut Microbiota as a Therapeutic Target to Ameliorate the Biochemical, Neuroanatomical, and Behavioral Effects of Traumatic Brain Injuries

Rice, M. W., Pandya, J. D., & Shear, D. A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00875 · Cited by 89 · see citing works

Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism

Dikeocha, I. J., Al‐Kabsi, A. M., Miftahussurur, M., & Alshawsh, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202101986r · Cited by 102 · see citing works

From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation

Bajic, J. E., Johnston, I. N., Howarth, G. S., & Hutchinson, M. R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00104 · Cited by 100 · see citing works

Anti-breast Cancer Enhancement of a Polysaccharide From Spore of Ganoderma lucidum With Paclitaxel: Suppression on Tumor Metabolism With Gut Microbiota Reshaping

Su, J., Li, D., Chen, Q., Li, M., Su, L., Luo, T. L., Liang, D., Lai, G., Shuai, O., Jiao, C., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03099 · Cited by 98 · see citing works

Constituents, Pharmacokinetics, and Pharmacology of Gegen-Qinlian Decoction

Lu, J., Ye, D., & Ma, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.668418 · Cited by 99 · see citing works

Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling

Su, J., Su, L., Li, D. X., Shuai, O., Zhang, Y., Liang, H., Jiao, C., Xu, Z., Lai, Y. R., & Xie, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01765 · Cited by 94 · see citing works

Of microbes and minds: A narrative review on the second brain aging

Calvani, R., Picca, A., Lo Monaco, M. R., Landi, F., Bernabei, R., & Marzetti, E. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00053 · Cited by 92 · see citing works

Microbiota–drug interactions: Impact on metabolism and efficacy of therapeutics

Wilkinson, E. M., Ilhan, Z. E., & Herbst‐Kralovetz, M. M. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.012 · Cited by 95 · see citing works

Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases

Kamel, M. S., Aleya, S., Alsubih, M., & Aleya, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020217 · Cited by 96 · see citing works

Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease

Crouwel, F., Buiter, H. J. C., & de Boer, N. K. H. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa143 · Cited by 90 · see citing works

Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption

Allwardt, V., Ainscough, A. J., Viswanathan, P., Sherrod, S. D., MCLEAN, J. A. J., Haddrick, M., & Pensabene, V. (2020) · Bioengineering · doi:10.3390/bioengineering7030112 · Cited by 89 · see citing works

Short-term particulate matter exposure influences nasal microbiota in a population of healthy subjects

Mariani, J., Favero, C., Spinazzè, A., Cavallo, D. M., Carugno, M., Motta, V., Bonzini, M., Cattaneo, A., Pesatori, A. C., & Bollati, V. (2017) · Environmental Research · doi:10.1016/j.envres.2017.12.016 · Cited by 88 · see citing works

Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice

Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 90 · see citing works

Development of the Gut Microbiome in Children, and Lifetime Implications for Obesity and Cardiometabolic Disease

Mohammadkhah, A. I., Simpson, E. B., Patterson, S. G., & Ferguson, J. F. (2018) · Children · doi:10.3390/children5120160 · Cited by 87 · see citing works

Polygonum multiflorum: Recent updates on newly isolated compounds, potential hepatotoxic compounds and their mechanisms

Teka, T., Wang, L., Gao, J., Mou, J., Pan, G., Yu, H., Gao, X., & Han, L. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113864 · Cited by 87 · see citing works

Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice

Gong, S., Feng, Y., Zeng, Y., Zhang, H., Pan, M., He, F., Wu, R., Chen, J., Lu, J., Zhang, S., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02814-5 · Cited by 87 · see citing works

New approach methodologies for exposure science

Wambaugh, J. F., Bare, J., Carignan, C. C., Dionisio, K. L., Dodson, R. E., Jolliet, O., Liu, X., Meyer, D. E., Newton, S., Phillips, K. A., et al. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.07.001 · Cited by 85 · see citing works

Interaction between gut microbiota and ethnomedicine constituents

Wu, X., & Tan, R. X. (2018) · Natural Product Reports · doi:10.1039/c8np00041g · Cited by 83 · see citing works

Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities

Yang, L., Zou, H., Gao, Y., Luo, J., Xie, X.-N., Meng, W., Zhou, H., & Tan, Z. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1714645 · Cited by 83 · see citing works

Current evidence linking diet to gut microbiota and brain development and function

Ceppa, F., Mancini, A., & Tuohy, K. M. (2018) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2018.1462309 · Cited by 82 · see citing works

Potential roles of gut microbes in biotransformation of natural products: An overview

Zhao, Y., Zhong, X., Yan, J., Sun, C., Zhao, X., & Wang, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.956378 · Cited by 82 · see citing works

Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications

Puig‐Castellví, F., Pacheco‐Tapia, R., Deslande, M., Jia, M., Andrikopoulos, P., Chechi, K., Bonnefond, A., Froguel, P., & Dumas, M. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117248 · Cited by 84 · see citing works

Ginger Alleviates DSS-Induced Ulcerative Colitis Severity by Improving the Diversity and Function of Gut Microbiota

Guo, S., Geng, W., Chen, S., Wang, L., Rong, X., Wang, S., Wang, T., Xiong, L., Huang, J., Pang, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632569 · Cited by 80 · see citing works

Gut microbiota: A magical multifunctional target regulated by medicine food homology species

Zuo, W., Pang, Q., Yao, L.-P., Zhang, Y., Peng, C. Y., Huang, W., & Han, B. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.05.011 · Cited by 81 · see citing works

Epigenetic effects of short-chain fatty acids from the large intestine on host cells

Stein, R. A., & Riber, L. (2023) · microLife · doi:10.1093/femsml/uqad032 · Cited by 81 · see citing works

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review

Li, H., Liang, J., Han, M., & Gao, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.004 · Cited by 79 · see citing works

Bioavailability Based on the Gut Microbiota: a New Perspective

Zhang, F., He, F., Li, L., Guo, L., Zhang, B., Yu, S., & Zhao, W. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00072-19 · Cited by 79 · see citing works

Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities

Leyva‐Gómez, G., Prado-Audelo, M. L. D., Ortega‐Peña, S., Mendoza‐Muñoz, N., Urbán‐Morlán, Z., González‐Torres, M., Carmen, M. G., Figueroa‐González, G., Reyes‐Hernández, O. D., & Cortés, H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050217 · Cited by 76 · see citing works

Impact of genistein on the gut microbiome of humanized mice and its role in breast tumor inhibition

Paul, B., Royston, K. J., Li, Y., Stoll, M. L., Skibola, C. F., Wilson, L. S., Barnes, S., Morrow, C. D., & Tollefsbol, T. O. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189756 · Cited by 74 · see citing works

Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs

Noh, K., Kang, Y.-R., Nepal, M. R., Shakya, R., Kang, M. J., Kang, W., Lee, S., Jeong, H. G., & Jeong, T. C. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0986-y · Cited by 74 · see citing works

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

Chau, J., Yadav, M., Liu, B., Furqan, M., Dai, Q., Shahi, S. K., Gupta, A. A., Mercer, K. N., Eastman, E., Hejleh, T. A., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08530-z · Cited by 75 · see citing works

Understanding the Complexities and Changes of the Astronaut Microbiome for Successful Long-Duration Space Missions

Tesei, D., Jewczynko, A., Lynch, A., & Urbaniak, C. (2022) · Life · doi:10.3390/life12040495 · Cited by 75 · see citing works

Microbiota and IBD: Current knowledge and future perspectives

Foppa, C., Rizkala, T., Repici, A., Hassan, C., & Spinelli, A. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.11.015 · Cited by 79 · see citing works

The metabolic effect of gut microbiota on drugs

Xie, Y., Hu, F., Xiang, D., Lu, H., Li, W., Zhao, A., Huang, L., & Wang, R. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1718691 · Cited by 72 · see citing works

Bringing microbiome-drug interaction research into the clinic

Guthrie, L., & Kelly, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.009 · Cited by 72 · see citing works

Gut microbiome and cardiovascular disease

Zhao, Y., & Wang, Z. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000720 · Cited by 68 · see citing works

A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats

Letertre, M. P. M., Munjoma, N. C., Wolfer, K., Pechlivanis, A., McDonald, J. A. K., Hardwick, R. N., Cherrington, N. J., Coen, M., Nicholson, J. K., Hoyles, L., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00230 · Cited by 69 · see citing works

The Gut Microbiome, Metformin, and Aging

Induri, S. N. R., Kansara, P., Thomas, S. C., Xu, F., Saxena, D. B., & Li, X. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051920-093829 · Cited by 66 · see citing works

Emulating Host-Microbiome Ecosystem of Human Gastrointestinal Tract in Vitro

Park, G.-S., Park, M. H., Shin, W., Zhao, C., Sheikh, S., Oh, S. J., & Kim, H. J. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9739-z · Cited by 69 · see citing works

Targeting the Microbiota in Pharmacology of Psychiatric Disorders

Pascale, A., Marchesi, N., Govoni, S., & Barbieri, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104856 · Cited by 67 · see citing works

Microbiome Is a Functional Modifier of P450 Drug Metabolism

Dempsey, J. L., & Cui, J. Y. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00200-w · Cited by 65 · see citing works

All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance

Hatton, G. B., Madla, C. M., Rabbie, S. C., & Basit, A. W. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.054 · Cited by 64 · see citing works

The Role of the Gut-Brain Axis in Attention-Deficit/Hyperactivity Disorder

Dam, S. A., Mostert, J. C., Szopinska-Tokov, J., Bloemendaal, M., Amato, M. P., & Vásquez, A. A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.05.001 · Cited by 63 · see citing works

Malaria and the Microbiome: A Systematic Review

Ippolito, M. M., Denny, J. E., Langelier, C., Sears, C. L., & Schmidt, N. W. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy374 · Cited by 63 · see citing works

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen

Zaza, G., Gassa, A. D., Felis, G. E., Granata, S., Torriani, S., & Lupo, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178228 · Cited by 63 · see citing works

The Modulation of Drug Efficacy and Toxicity by the Gut Microbiome

Wilson, I. D., & Nicholson, J. K. (2014) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6539-2_15 · Cited by 9 · see citing works

Gut microbiota and drug metabolism: the forgotten organ

{"name":"Kamatham Udayasri", ". C., {"name":"Achutha Giridhar", ". C., & {"name":"Yadala Prapurna Chandra", ". C. (2026) · International Journal of Experimental and Biomedical Research · doi:10.26452/ijebr.v5i1.544

Gut microbiota impact on drug metabolism, bioavailability, and biotransformation

Boyle, N. R., & Patterson, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29289-7.00019-9

Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs

Noh, K., Kang, Y.-R., Nepal, M. R., Shakya, R., Kang, M. J., Kang, W., Lee, S., Jeong, H. G., & Jeong, T. C. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0986-y · Cited by 74 · see citing works

Understanding and role of gut microbiota on drug response and toxicity

Seshadri, S., Gajjar, D., Joshi, A., Bhatia, Z., & Kumar, S. (2024) · Journal of Toxicological Studies · doi:10.59400/jts.v2i1.1252 · Cited by 3 · see citing works